Anika Therapeutics (NASDAQ:ANIK) Stock Price Crosses Below 200-Day Moving Average Following Weak Earnings

Key Points

• Anika Therapeutics shares fell below their 200-day moving average of $16.25, trading as low as $13.90, after earnings missed the cited consensus: quarterly EPS was $0.29 versus $0.42 expected.
• Revenue rose 10% year over year to $30.59 million, topping the $29.44 million estimate; commercial-channel revenue grew 17%, including growth of more than 30% for Integrity.
• The company raised the lower end of its 2026 revenue guidance and increased its adjusted EBITDA outlook, while announcing a new 10-year Hyvisc partnership with improved economics.

Anika Therapeutics Inc. (NASDAQ:ANIK - Get Free Report) shares passed below its 200-day moving average during trading on Friday after the company announced weaker than expected quarterly earnings. The stock has a 200-day moving average of $16.25 and traded as low as $13.90. Anika Therapeutics shares last traded at $14.55, with a volume of 294,030 shares traded.

The biotechnology company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.13). Anika Therapeutics had a negative net margin of 3.14% and a positive return on equity of 0.20%. The company had revenue of $30.59 million during the quarter, compared to the consensus estimate of $29.44 million.

More Anika Therapeutics News

Here are the key news stories impacting Anika Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 10% year over year to $30.59 million, beating the cited analyst estimate of $29.44 million. Commercial-channel revenue grew 17%, with Integrity revenue up more than 30%. Anika Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Anika raised the lower end of its 2026 revenue guidance and increased its adjusted EBITDA outlook. It forecast revenue of $119.6 million to $124.1 million, a range that includes the $121.6 million consensus estimate. Anika Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company secured a new 10-year Hyvisc partnership with improved economics and reintroduced a Hyaff product for non-orthopedic original-equipment-manufacturer customers, offering potential longer-term commercial support. Anika Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Adjusted EPS was reported at $0.29, above Zacks’ $0.17 estimate, while the cited results also show a GAAP loss of $0.02 per share. Analyst estimates differ across reports, making the earnings comparison mixed. Anika Therapeutics Beats Q3 Earnings and Revenue Estimates
• Negative Sentiment: The GAAP loss and reported EPS misses against some analyst benchmarks may have weighed on sentiment, despite the revenue beat and stronger adjusted-EPS comparison. Anika Therapeutics GAAP EPS and Revenue Results

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Zacks Research lowered Anika Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 28th. B. Riley Financial started coverage on Anika Therapeutics in a report on Friday, September 18th. They set a "buy" rating and a $23.00 target price for the company. Barrington Research set a $21.00 target price on shares of Anika Therapeutics in a report on Thursday, July 30th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Anika Therapeutics in a research report on Monday, September 21st. Finally, Wall Street Zen upgraded shares of Anika Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $22.00.

Institutional Trading of Anika Therapeutics

Several hedge funds have recently bought and sold shares of ANIK. Russell Investments Group Ltd. raised its holdings in Anika Therapeutics by 22.3% during the third quarter. Russell Investments Group Ltd. now owns 10,282 shares of the biotechnology company's stock valued at $202,000 after acquiring an additional 1,873 shares during the period. Blueprint Investment Partners LLC purchased a new position in shares of Anika Therapeutics during the 3rd quarter worth about $347,000. Blueprint Financial Advisors LLC purchased a new stake in Anika Therapeutics in the third quarter worth $347,000. Simplicity Wealth LLC bought a new position in Anika Therapeutics in the 3rd quarter worth about $285,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Anika Therapeutics during the second quarter valued at $274,000. Institutional investors own 91.53% of the company's stock.

Anika Therapeutics Price Performance

The business has a fifty day simple moving average of $20.38 and a two-hundred day simple moving average of $16.25. The company has a market cap of $194.68 million, a PE ratio of -53.89, a price-to-earnings-growth ratio of 13.86 and a beta of 0.21.

About Anika Therapeutics

Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.

Anika's orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.